# The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

> **NCT00548327** · PHASE2 · TERMINATED · sponsor: **National Institute of Mental Health (NIMH)** · enrollment: 11 (actual)

## Conditions studied

- Schizophrenia
- Memory Disorders
- Cognition Disorders

## Interventions

- **DRUG:** Atomoxetine
- **PROCEDURE:** Functional magnetic resonance imaging
- **PROCEDURE:** Neuropsychological Testing
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00548327
- **Lead sponsor:** National Institute of Mental Health (NIMH)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2011-11
- **Final completion:** 2011-11
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** The scientific director decided to terminate: low priority study with slow accrual
- **Last updated:** 2013-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00548327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00548327, "The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00548327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*